c-MET
Catalog No. | Inhibitor Name | c-Met | Other |
---|---|---|---|
A10712 | Crizotinib | * | ALK |
A10996 | Cabozantinib | *** | VEGFR2/KDR,Kit,VEGFR3/FLT4 |
A10998 | Foretinib | **** | KDR,Tie-2,VEGFR3/FLT4 |
A10713 | PHA-665752 | ** | RON,Flk1,c-Abl |
A10869 | SU11274 | ** | Flk1,RON,FGFR1 |
A10839 | SGX-523 | *** | |
A10153 | BMS-777607 | *** | Axl,RON,Tyro3 |
A11087 | Tivantinib | * | |
A10493 | JNJ-38877605 | *** | |
A10711 | PF-04217903 | ** | |
A10587 | MGCD-265 | **** | RON,VEGFR2,VEGFR1 |
A11132 | Capmatinib | **** | |
A11059 | BMS-754807 | ** | Insulin Receptor,IGF-1R,TrkB |
A10154 | BMS-794833 | *** | VEGFR2 |
A10063 | AMG-208 | ** | |
A11753 | MK-2461 | **** | c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100) |
A11396 | Golvatinib | * | VEGFR2 |
A11055 | AMG-458 | **** | VEGFR2 |
A11257 | Tepotinib | *** | IRAK4,TrkA,Axl |
A11150 | NVP-BVU972 | * | |
A12557 | Merestinib | *** | |
A15917 | NPS-1034 | * | Axl |
A11489 | MK-8033 | **** | Ron |
A14387 | Altiratinib | *** | TIE-2, VEGFR |
A14419 | Volitinib (Savolitinib, AZD-6094) | ||
A15792 | BMS-817378 | *** | VEGFR2 |
Notes:
1.Hover mouse over " " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
-
LY2801653 dihydrochloride
Catalog No. A15150 -
PF-04217903 methanesulfonate
Catalog No. A15208 c-Met 抑制剂PF-04217903 methanesulfonate是一种选择性ATP竞争性c-Met抑制剂,IC50为4.8 nM,易致癌突变(对Y1230C突变体无活性)。 了解更多 -
BMS-817378
Catalog No. A15792 -
Altiratinib (DCC2701)
Catalog No. A14387 c-Met/VEGFR 抑制剂Altiratinib (DCC2701)是一种新型的c-MET/TIE-2/VEGFR抑制剂;与体外HGF拮抗剂相比,可有效降低体内的肿瘤负荷并阻断c-MET pTyr(1349)介导的信号传导,细胞生长和迁移。 了解更多 -
ARQ 197 (Tivantinib)
Catalog No. A11087 c-Met 抑制剂ARQ-197是c-Met受体酪氨酸激酶的选择性抑制剂, 在无细胞试验中Ki为0.355 μM,对Ron几乎没有作用活性,对EGFR, InsR, PDGFRα和FGFR1/4没有抑制作用。 了解更多 -
BMS-754807
Catalog No. A11059 IGF-1R 抑制剂BMS-754807是一种有效的,口服活性生长因子1受体/胰岛素受体家族靶向的激酶抑制剂。 了解更多 -
LY2801653 (Merestinib)
Catalog No. A12557 -
c-Met inhibitor 2
Catalog No. A16256 -
Glesatinib hydrochloride
Catalog No. A16257 -
Foretinib (GSK1363089, XL880)
Catalog No. A10998 c-MET 抑制剂Foretinib (GSK1363089,XL880)是c-Met和VEGFR-2的多激酶抑制剂,可抑制增殖,诱导Anoikis并损害卵巢癌转移。 了解更多 -
XL184 free base (Cabozantinib)
Catalog No. A10996 VEGFR 抑制剂XL184 free base (Cabozantinib)是设计用来抑制多种受体酪氨酸激酶(特别是MET和VEGFR2)的小分子。 了解更多 -
PF-2341066 (Crizotinib)
Catalog No. A10712 ALK/ c-Met 抑制剂PF-2341066 (Crizotinib)是c-Met激酶和NPM-ALK的抑制剂。PF-2341066抑制ALK阳性ALCL细胞中的细胞增殖(IC50 = 30 nM)。 了解更多 -
Glumetinib (SCC-244)
Catalog No. A18328 c-Met inhibitorGlumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC50 of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin. 了解更多 -
JNJ-38877618
Catalog No. A18325 c-Met inhibitorJNJ-38877618 is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. 了解更多 -
BMS 777607
Catalog No. A21638 c-Met/Axl/Ron/Tyro3 inhibitorBMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. 了解更多 -
c-Met inhibitor 1
Catalog No. A15049 -
Volitinib (Savolitinib, AZD-6094)
Catalog No. A14419 -
EMD-1214063
Catalog No. A11257 c-Met 抑制剂EMD-1214063是MET酪氨酸激酶的抑制剂,IC50为4 nM,作用于c-Met比作用于IRAK4, TrkA, Axl, IRAK1和Mer选择性高200倍以上。具有潜在的抗肿瘤活性。它与MET酪氨酸激酶结合并破坏MET信号转导途径,这可能在过表达该激酶的肿瘤细胞中诱导凋亡。 了解更多 -
AMG-458
Catalog No. A11055 -
BMS-794833
Catalog No. A10154 -
AMG 208
Catalog No. A10063 -
PF-04217903
Catalog No. A10711 c-Met 抑制剂PF-04217903是一种选择性的,ATP竞争性c-Met抑制剂,在A549细胞中IC50为4.8 nM,对致癌基因突变型敏感(对Y1230C突变型没有活性)。 了解更多 -
MGCD-265 (Glesatinib)
Catalog No. A10587 c-Met 抑制剂MGCD-265 (Glesatinib)是一种多靶酪氨酸激酶抑制剂,可与多种RTK(包括c-Met受体(HGFR)结合并抑制其磷酸化。Tek/Tie-2受体;VEGFR类型1、2和3;和MST1R。 了解更多 -
BMS-777607
Catalog No. A10153 c-Met 抑制剂BMS-777607是一种MET酪氨酸激酶抑制剂,与c-Met蛋白或HGFR结合,可防止HGF结合并破坏MET信号通路。 了解更多 -
JNJ-38877605
Catalog No. A10493 -
PHA-665752
Catalog No. A10713